HONG KONG, May 21, 2025 – We are thrilled to announce that today, May 21, 2025, Eagle IP celebrates its 20th anniversary, marking two decades of dedication to client success and innovation in patent law. Founded on May 21, 2005 by Dr. Jacqueline Lui (Jackie), the firm has grown from its humble beginnings into a respected name in the industry.

In a recent team celebration, Jackie, the firm’s founder, shared her reflections on Eagle IP’s journey. “Starting Eagle IP was a leap of faith driven by my commitment to my clients and their patent portfolios,” she said. “Transferring two significant portfolios laid the foundation for the beginnings of the firm and paved the way towards our success. I’m grateful for the perseverance that carried us through tough times. Our CPR culture—caring, professional, and responsive—has defined who we are and will guide us forward.”

The anniversary event highlighted the firm’s strong culture, with team members who have been with the firm for over a decade sharing memories of growth under Jackie’s leadership.

Jennifer Che, current President and Managing Director who “took the baton” of Eagle IP leadership last year from Jackie, expressed her commitment to upholding these values while driving expansion, noting the firm’s increasing client base and active participation in global conferences.

Eagle IP looks to the future with optimism, dedicated to maintaining its high standards, fostering continuous learning, and building stronger team relationships. Jackie and her husband HC Lui emphasized the power of teamwork, assuring continued support as the firm embarks on its next chapter.

A huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines[1] (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
Top crossarrow-right